Aligos Therapeutics To Present Multiple Posters At AASLD's The Liver Meeting 2023, Highlighting Progress For Its Clinical Stage Portfolio, including Lead THR-β Agonist For The Treatment Of NASH, ALG-055009; ALG-000184, The Company's Lead CAM-E Molecule
Portfolio Pulse from Benzinga Newsdesk
Aligos Therapeutics, Inc. (NASDAQ:ALGS) announced it will present six posters at the American Association for the Study of Liver Diseases' The Liver Meeting® 2023. The posters will include clinical and preclinical data on the nonalcoholic steatohepatitis (NASH) program, ALG-055009, currently in Phase 2-enabling studies, and data from the chronic hepatitis B (CHB) portfolio.
November 07, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aligos Therapeutics' announcement to present data on its NASH and CHB programs at a major conference could potentially increase investor interest and confidence in the company.
Presenting at a major conference increases visibility and can attract potential investors. The data presented could also provide validation for the company's programs, potentially leading to increased investor confidence and a positive impact on the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100